Test it yourself. If it fails, you get a full refund.
Independent test fails? Full refund.
Independent test fails? Full refund.
10 vials per kit, from 1 kit per product and strength. We reply to every quote request within 24 hours. How quotes work →
10 vials per kit · from 1 kit · reply within 24 hours Quotes →
10 vials per kit · from 1 kit Quotes →
Research topic
The GLP-1 class — Semaglutide, Tirzepatide, Retatrutide, Mazdutide, Survodutide — with Cagrilintide, and the auxiliary materials AOD9604, 5-Amino-1MQ, L-Carnitine, Lemon Bottle, Lipo-C and MIC + B12.
The peptides of this topic act on receptors of gut and pancreatic hormones: GLP-1 alone (Semaglutide), GLP-1 with GIP (Tirzepatide), with glucagon (Mazdutide, Survodutide) or with both (Retatrutide), and the amylin receptors (Cagrilintide). Their pages list every strength per vial with its catalogue code, the identity data with sources, and the discovery papers and trials in our product data.
Semaglutide, Tirzepatide and — in China — Mazdutide are the active ingredients of approved medicines, and so is L-Carnitine as levocarnitine. What we supply is the same molecule in each case, but not a medicine: research material in vials. The auxiliary materials form their own group; Lemon Bottle, Lipo-C and MIC + B12 are blends whose composition the COA of each lot states.
Semaglutide, Tirzepatide, Retatrutide, Mazdutide and Survodutide — GLP-1 receptor agonists alone or with GIP and glucagon activity — and Cagrilintide, an amylin analogue.
Grouped by the receptor activity described in the discovery paper or trial cited on each page.
Lipidated GLP-1 receptor agonist peptide of 31 residues
Dual GIP and GLP-1 receptor agonist peptide of 39 residues
Triple GIP, GLP-1 and glucagon receptor agonist peptide (LY3437943)
37-mer
Long-acting lipidated amylin analogue of 37 residues
Dual GLP-1 and glucagon receptor agonist peptide (IBI362 / LY3305677)
Dual glucagon and GLP-1 receptor agonist peptide (BI 456906)
AOD9604, 5-Amino-1MQ and L-Carnitine, and the solutions Lemon Bottle, Lipo-C and MIC + B12 — materials buyers order alongside the GLP-1 class.
Listed together because buyers of the body-composition topic order them; not a literature class.
Multi-ingredient aqueous solution known by a trade name
Methionine, inositol and choline solution with B vitamins
Methionine, inositol and choline with vitamin B12
The (R)-enantiomer of carnitine, supplied as a solution
16-mer
Tyrosine-extended growth-hormone fragment, 16 residues
Small-molecule NNMT inhibitor, supplied as the iodide salt
The studies recorded in our product data for the products of this topic (checked 2026-10-09): who led the study or which trial it was, the year, the journal and what was examined. They show what has been researched with each molecule, not results for the vials we supply.
| Product | First author / trial | Year | Journal | What was studied | Record |
|---|---|---|---|---|---|
| Semaglutide | Lau J | 2015 | J Med Chem | Design and discovery of semaglutide as a long-acting GLP-1 analogue | PubMed 26308095 |
| Semaglutide | Marso SP | 2016 | N Engl J Med | Cardiovascular outcomes in people with type 2 diabetes (SUSTAIN-6) | PubMed 27633186 |
| Semaglutide | Garvey WT | 2022 | Nat Med | Two-year trial in adults with overweight or obesity (STEP 5) | PubMed 36216945 |
| Semaglutide | Lincoff AM | 2023 | N Engl J Med | Cardiovascular outcomes in people with obesity and no diabetes (SELECT) | PubMed 37952131 |
| Tirzepatide | SURPASS-2 trial | 2021 | N Engl J Med | Tirzepatide compared with semaglutide in people with type 2 diabetes | PubMed 34170647 |
| Tirzepatide | SURMOUNT-1 trial | 2022 | N Engl J Med | Adults with obesity and without diabetes | PubMed 35658024 |
| Tirzepatide | SURMOUNT-OSA trial | 2024 | N Engl J Med | Adults with obstructive sleep apnoea and obesity | PubMed 38912654 |
| Tirzepatide | SURPASS-CVOT trial | 2025 | N Engl J Med | Cardiovascular outcomes compared with dulaglutide in type 2 diabetes | PubMed 41406444 |
| Retatrutide | Coskun T | 2022 | Cell Metab | Discovery of LY3437943: cell and mouse pharmacology and a first human study | PubMed 35985340 |
| Retatrutide | Jastreboff AM | 2023 | N Engl J Med | Phase 2 trial in adults with obesity | PubMed 37366315 |
| Retatrutide | Rosenstock J | 2023 | Lancet | Phase 2 trial in people with type 2 diabetes | PubMed 37385280 |
| Retatrutide | Coskun T | 2025 | Lancet Diabetes Endocrinol | Body-composition substudy of a phase 2 trial in type 2 diabetes | PubMed 40609566 |
| Cagrilintide | Kruse T | 2021 | J Med Chem | Development of cagrilintide as a long-acting amylin analogue | PubMed 34288673 |
| Cagrilintide | Cao Y | 2025 | Nat Commun | Cryo-EM structures of cagrilintide bound to amylin and calcitonin receptors | DOI |
| Cagrilintide | Lau DCW | 2021 | Lancet | Phase 2 trial of cagrilintide alone in people with overweight or obesity | PubMed 34798060 |
| Cagrilintide | Gabe MBN | 2024 | Diabetes Obes Metab | Thorough QT study in healthy participants | PubMed 39279639 |
| Cagrilintide | Frias JP | 2023 | Lancet | Cagrilintide with semaglutide in type 2 diabetes(combination) | PubMed 37364590 |
| Mazdutide | Jiang H | 2022 | Nat Commun | Phase 1b trial of IBI362 in people with type 2 diabetes | PubMed 35750681 |
| Mazdutide | Ji L | 2025 | N Engl J Med | Phase 3 trial in Chinese adults with obesity or overweight (GLORY-1) | PubMed 40421736 |
| Mazdutide | Shirley M | 2025 | Drugs | Profile of the molecule at its first approval | PubMed 41028652 |
| Mazdutide | Dong W | 2025 | EBioMedicine | Mechanism study of cognition in diabetic mouse models | PubMed 40479843 |
| Survodutide | SYNCHRONIZE-1 trial | 2026 | N Engl J Med | Phase 3 trial in adults with obesity | PubMed 42253238 |
| Survodutide | SYNCHRONIZE-MASLD trial | 2026 | Nat Med | Adults with obesity and metabolic dysfunction-associated fatty liver disease | PubMed 42252333 |
| Survodutide | SYNCHRONIZE-2 trial | 2026 | Diabetes Obes Metab | Baseline characteristics of a phase 3 trial in people with obesity and type 2 diabetes | PubMed 41216778 |
| L-Carnitine | Pande SV | 1975 | Proc Natl Acad Sci U S A | The mitochondrial carnitine–acylcarnitine translocase | PubMed 1055387 |
| L-Carnitine | Chase JF | 1966 | Biochem J | Kinetics of carnitine acetyltransferase | PubMed 5965344 |
| L-Carnitine | Rebouche CJ | 1977 | Biochim Biophys Acta | Carnitine movement across the membranes of isolated rat muscle | PubMed 921970 |
| AOD9604 | Ng FM | 2000 | Horm Res | Metabolic studies of the synthetic peptide in obese rats | PubMed 11146367 |
| AOD9604 | Heffernan M | 2001 | Endocrinology | Lipid metabolism in obese mice, compared with human growth hormone | PubMed 11713213 |
| AOD9604 | Cox HD | 2015 | Drug Test Anal | Analytical detection of AOD9604 and its metabolism in vitro | PubMed 25208511 |
| AOD9604 | Stier H | 2013 | J Endocrinol Metab | Pooled safety and tolerability data from sponsor-funded human trials | DOI |
| 5-Amino-1MQ | Neelakantan H | 2017 | J Med Chem | Structure–activity relationships of small-molecule NNMT inhibitors | PubMed 28548833 |
| 5-Amino-1MQ | Neelakantan H | 2018 | Biochem Pharmacol | Membrane-permeable NNMT inhibitors in mice on a high-fat diet | PubMed 29155147 |
| 5-Amino-1MQ | Kraus D | 2014 | Nature | Knock-down of the target enzyme, NNMT, in mice on a high-fat diet | PubMed 24717514 |
| 5-Amino-1MQ | Awosemo O | 2021 | J Pharm Biomed Anal | An LC-MS/MS method for the compound in rat plasma | PubMed 34304009 |
Every lot of a stocked product has its own batch COA. Ask for the COA of the batch you are quoted before you order: the lot number on it is the lot we ship.
What the COA reportsSemaglutide, Tirzepatide, Retatrutide, Cagrilintide, Mazdutide, Survodutide, Lemon Bottle, Lipo-C, MIC + B12, L-Carnitine, AOD9604, 5-Amino-1MQ — each with catalogue codes, kits of 10 vials from 1 kit, and a batch COA for every lot.
Semaglutide, Tirzepatide, Mazdutide and L-Carnitine are the same molecules as the active ingredients of approved medicines; Retatrutide, Survodutide and Cagrilintide are investigational. In every case we supply research material in vials, which is not a medicine.
Every strength in our product table, each from one kit of ten vials. The product pages list the strengths with their catalogue codes; one quotation can combine several.
Lemon Bottle and Lipo-C are aqueous blends in 10 ml vials, and L-Carnitine is listed as a solution; our product table records no form for MIC + B12. The COA of each lot states composition, assay and fill.
No, it is an amylin analogue. It sits in this group because studies often pair it with GLP-1 agonists.
Name the products, strengths and number of kits, and your country. One written quote can cover several products — we reply within 24 hours.
